• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

作者信息

Ledermann J A, Raja F A, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C

出版信息

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv259. doi: 10.1093/annonc/mdy157.

DOI:10.1093/annonc/mdy157
PMID:30285216
Abstract
摘要

相似文献

1
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.新诊断及复发的上皮性卵巢癌：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv259. doi: 10.1093/annonc/mdy157.
2
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.新诊断及复发的上皮性卵巢癌：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2023 Oct;34(10):833-848. doi: 10.1016/j.annonc.2023.07.011. Epub 2023 Aug 17.
3
Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.新发及复发性上皮性卵巢癌：ESMO关于诊断、治疗及随访的临床建议
Ann Oncol. 2009 May;20 Suppl 4:21-3. doi: 10.1093/annonc/mdp117.
4
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.新诊断及复发的滤泡性淋巴瘤：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2017 Dec 1;28(12):3109. doi: 10.1093/annonc/mdx020.
5
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.新诊断及复发滤泡性淋巴瘤：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2016 Sep;27(suppl 5):v83-v90. doi: 10.1093/annonc/mdw400.
6
Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.新诊断及复发滤泡性淋巴瘤：ESMO关于诊断、治疗及随访的临床建议
Ann Oncol. 2009 May;20 Suppl 4:119-20. doi: 10.1093/annonc/mdp148.
7
EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Mantle Cell Lymphoma.欧洲血液学协会（EHA）认可欧洲肿瘤内科学会（ESMO）关于新诊断和复发套细胞淋巴瘤的临床实践指南。
Hemasphere. 2020 Aug 17;4(5):e464. doi: 10.1097/HS9.0000000000000464. eCollection 2020 Oct.
8
EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Follicular Lymphoma.欧洲血液学协会（EHA）认可欧洲医学肿瘤学会（ESMO）关于新诊断和复发滤泡性淋巴瘤的临床实践指南。
Hemasphere. 2021 Apr 21;5(5):e559. doi: 10.1097/HS9.0000000000000559. eCollection 2021 May.
9
Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer - ESMO-MCBS scores.晚期卵巢癌一线争议性全身治疗的临床获益 - ESMO-MCBS 评分。
Cancer Treat Rev. 2018 Sep;69:233-242. doi: 10.1016/j.ctrv.2018.06.008. Epub 2018 Jun 18.
10
Non-epithelial ovarian cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.非上皮性卵巢癌：ESMO关于诊断、治疗及随访的临床建议
Ann Oncol. 2009 May;20 Suppl 4:24-6. doi: 10.1093/annonc/mdp118.

引用本文的文献

1
Association of Tumor-Infiltrating Lymphocytes and Inflammation Status with Survival Outcome in Patients with High-Grade Serous Ovarian Carcinoma.高级别浆液性卵巢癌患者肿瘤浸润淋巴细胞及炎症状态与生存结局的相关性
Cancers (Basel). 2025 Jul 8;17(14):2269. doi: 10.3390/cancers17142269.
2
Demographic trends in mortality due to ovarian cancer in the United States, 1999-2020.1999 - 2020年美国卵巢癌死亡率的人口统计学趋势
World J Clin Oncol. 2025 Jun 24;16(6):108393. doi: 10.5306/wjco.v16.i6.108393.
3
Berberine inhibits metastasis of ovarian cancer by blocking lipid metabolism, alleviating aging of adipose tissue and increasing tumor infiltrating immune cells.
黄连素通过阻断脂质代谢、减轻脂肪组织衰老及增加肿瘤浸润免疫细胞来抑制卵巢癌转移。
Transl Oncol. 2025 Jun;56:102380. doi: 10.1016/j.tranon.2025.102380. Epub 2025 Apr 19.
4
Homologous recombination deficiency test validation in patients with high-grade advanced ovarian cancer.高级别晚期卵巢癌患者同源重组缺陷检测的验证
Front Mol Biosci. 2025 Feb 11;12:1524594. doi: 10.3389/fmolb.2025.1524594. eCollection 2025.
5
Targeting the SPC25/RIOK1/MYH9 Axis to Overcome Tumor Stemness and Platinum Resistance in Epithelial Ovarian Cancer.靶向SPC25/RIOK1/MYH9轴以克服上皮性卵巢癌的肿瘤干性和铂耐药性
Adv Sci (Weinh). 2024 Dec;11(47):e2406688. doi: 10.1002/advs.202406688. Epub 2024 Nov 3.
6
Predicting prognosis for epithelial ovarian cancer patients receiving bevacizumab treatment with CT-based deep learning.基于CT的深度学习预测接受贝伐单抗治疗的上皮性卵巢癌患者的预后
NPJ Precis Oncol. 2024 Sep 13;8(1):202. doi: 10.1038/s41698-024-00688-6.
7
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach.卵巢癌的免疫治疗：迈向基于个体化免疫表型的方法。
Nat Rev Clin Oncol. 2024 Nov;21(11):801-817. doi: 10.1038/s41571-024-00937-4. Epub 2024 Sep 4.
8
Radical total pelvic exenteration with concomitant right nephrectomy in the management of recurrent endometrioid ovarian adenocarcinoma: A case report and literature review.根治性全盆腔脏器切除术联合右肾切除术治疗复发性子宫内膜样卵巢腺癌：1例病例报告及文献综述
Clin Case Rep. 2024 Jul 3;12(7):e9148. doi: 10.1002/ccr3.9148. eCollection 2024 Jul.
9
Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group.高级别浆液性卵巢癌的同源重组 proficient 亚型：预后不良组的治疗选择
Front Oncol. 2024 Jun 4;14:1387281. doi: 10.3389/fonc.2024.1387281. eCollection 2024.
10
Construction of ROS-Responsive Hyaluronic Acid Modified Paclitaxel and Diosgenin Liposomes and Study on Synergistic Enhancement of Anti-Ovarian Cancer Efficacy.构建 ROS 响应性透明质酸修饰的紫杉醇和薯蓣皂苷元脂质体及协同增强抗卵巢癌作用的研究。
Int J Nanomedicine. 2024 Jun 5;19:5193-5211. doi: 10.2147/IJN.S455942. eCollection 2024.